Canton-based Organogenesis, which manufactures an organic skin patch used to promote skin growth for chronic-wound sufferers, is is moving into a new research lab and headquarters this spring as it expands manufacturing space to meet increasing demand, the Enterprise reports.
As the Enterprise notes, Organogenesis expects to add 100 staffers to its 500-strong workforce by the end of the year. Apligraf, the company's skin patch, gained FDA approval in 1999, and as the Enterprise notes, 450,000 units have been shipped to doctors to treat patients’ slow-to-heal diabetic foot ulcers and venous leg ulcers.
